Cellular Intelligence

Today we’re sharing a defining moment for Cellular Intelligence. We have entered into an agreement with @novonordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease. Alongside the acquisition, Novo Nordisk is making a strategic investment in Cellular Intelligence. This is one of the most advanced cell therapy programs in Parkinson’s. The program has an FDA-cleared IND for Phase 2 and Fast Track Designation, following completion of Phase 1/2 dosing in the underlying academic clinical program, STEM-PD. This is more than an asset acquisition. It marks the beginning of an AI-native era for cell replacement therapy. One where biology is no longer destiny, but design. Read all about it here: cellularintelligence.com/stem-pd?utm-so… #CellTherapy #ParkinsonsDisease #Biotech #AIinBiotech #TechBio STEM-PD is an investigational therapy; its safety and efficacy have not been established.

Founders & Leadership Team: @MichaBreakstone, Olivier Pourquie, @JShendure, @arjunrajlab, @KleinLabHMS, Cliff Tabin, @TweetKJBrown, Tzvika Cohen, @SamanthaDStrass, Nuno Mendonça, Marianne Stemann Andersen.

Keynote & Speakers: Mads Krogsgaard Thomsen, @nasdaily, @MatttBuckley, Thomas Carlsen, @StephanChr25527, @andreascleve, @johncumbers, @VitalayFomin, Gunner Laine Hardy, @kim_bak_jensen, Petrina Kamya, @Kirkeby_Lab, @MatLegut, @aijamayrock, @jb_michel, Jens Nielsen, @ParmarLab , Travis Potter, Tali Raveh, @ArmonSharei, @ReshefShilon, @NTallapragada, @aloktayi, @VallierLab, @PeterAksel

What is the future of AI x Bio? Yesterday in Copenhagen, we set out to answer exactly that. At the @novonordiskfond headquarters, we convened leaders across AI, biology, regenerative medicine, venture, and company building for a day-long symposium on Engineering Cell Fate—and what we believe will become the next AlphaFold moment for biology. 🧵

This week at the @KeystoneSymp on Computational Advances in Drug Discovery, our VP of Strategy @SamanthaDStrass gave a spotlight talk, and @baagmery, Principal Scientist in Computational Biology, presented on the poster floor — joining the conversation at the frontier of computational drug discovery. Their talk and poster showcased our multiplexed platform and its ability to generate data at unprecedented scale — the foundation for our work toward a Universal Virtual Cell-Signaling Model that predicts context-dependent signaling response and, ultimately, controls cell fate. This unlocks a range of applications: iPSC-based disease modeling, drug response prediction, target identification, and protocol design for cell therapies. These capabilities turn biology from a trial-and-error science into predictive engineering. Thank you to Keystone Symposia for the opportunity to share our work. We're building a future where biology is no longer destiny, but design. #ksdrugdiscovery2026 @arjunrajlab, Kristy Brown, @KleinLabHMS, Olivier Pourquié

We are incredibly energized by the breakthroughs happening alongside us, and believe that as we learn causal cellular grammar, we are building a future where biology is no longer destiny, but design.

By capturing this scale, we can look at biology not as static states, but as dynamic transitions. We are moving away from empirical trial-and-error to essentially learning the grammar of cellular decision-making, which fundamentally transforms how we can engineer cell therapies and model disease.

Today, our CEO @MichaBreakstone joined a brilliant panel alongside @iamjohnnyyu from @tahoe_ai and @glebkuz from @ManifoldBio—masterfully moderated by @FabioZB_I of Polyphron—to answer a pivotal question: Why now?  🧵

Our CEO @MichaBreakstone just stepped off the stage at #SynBioBeta2026. The energy in the room was electric, confirming what we've believed since day one at Cellular Intelligence: Biology is ready to be transformed from trial-and-error into a true engineering discipline. Thank you @SynBioBeta for the platform to share our vision. We are building a future where biology is no longer destiny, but design.

In just one hour at #SynBioBeta2026, our CEO @MichaBreakstone takes the stage to outline the future of cellular engineering. Join us. We are building a future where biology is no longer destiny, but design. Thanks @SynBioBeta for the stage.

Joining them on stage: @MatttBuckley, Thomas Carlsen, @StephanChr25527, @VitalayF, Gunner Laine Hardy, @Kirkeby_Lab, JB Michel, Jens Nielsen, Malin Parmar, Travis Potter, Tali Raveh, Reshef Shilon, Ludovic Vallier, @PeterAksel.

We are honored to feature Keynote & Speakers: @nasdaily, @andreascleve, @johncumbers, @kim_bak_jensen, @PetrinaKamya, @MatLegut, @aijamayrock, @ArmonSharei, @NTallapragada, @aloktayi.

The future of medicine is converging in Copenhagen! On May 12, we are thrilled to host a full-day AI x Bio symposium at @novonordiskfond HQ. NNF CEO Mads Krogsgaard will keynote alongside 25+ global experts.🧵